A clinical-stage biopharmaceutical company developing new treatments for eye and neuro-ophthalmic diseases, working on easy-to-use eye drops to address conditions like optic neuritis. Its roots stretch to a group founded in Reykjavik, Iceland, in 2003, and it is now based in Zug, Switzerland. The name comes from the Latin word "oculus," meaning eye, and the company listed on the Nasdaq stock exchange in 2023 after merging with a European biotech acquisition company.
Oculis updates corporate presentation highlighting Privosegtor and Licaminlimab progress
Oculis Holding AG filed a Form 6-K on June 25, 2026, updating its corporate presentation for investor meetings.
Show detailsHide details
Privosegtor, a neuroprotective candidate for optic neuritis, has FDA Breakthrough Therapy and EMA PRIME designations, with PIONEER-1 enrollment completion expected in 2027.
Licaminlimab, a genotype-based dry eye disease candidate, anticipates topline results from the PREDICT-1 trial around year-end 2026.
The company reports a strong balance sheet with no debt and a cash runway into 2H 2029, excluding a CHF100m loan facility.
Phase 2 ACUITY trial data for Privosegtor showed clinically meaningful visual function improvement and neuroprotection in optic neuritis patients.
Oculis reports DIAMOND Phase 3 trials of OCS-01 in DME missed primary endpoint; no FDA filing planned
Both DIAMOND-1 and DIAMOND-2 Phase 3 trials of OCS-01 eye drops in diabetic macular edema failed to meet the primary endpoint of mean change in BCVA at Week 52.
Show detailsHide details
The secondary endpoint of retinal thickness (CST) showed substantial and persistent reduction with OCS-01 vs vehicle in both trials.
Oculis will not pursue an FDA regulatory filing for OCS-01 in DME at this time.
Company will focus on Privosegtor PIONEER program in optic neuropathies and Licaminlimab PREDICT-1 trial in dry eye disease.
Cash position of $278 million as of March 31, 2026, provides runway into 2H 2029.
Oculis Holding AG publishes invitation to 2026 Annual General Meeting on May 13, 2026
The 2026 Annual General Meeting will be held in-person on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, Zug, Switzerland, at 6:00 a.m. EDT / 12:00 p.m. CEST.
Show detailsHide details
The agenda includes approval of the 2025 annual report, allocation of the CHF 80,247,000 balance sheet loss, discharge of board and executive committee, and re-election of all current board members plus new candidate Gregory D. Perry.
Shareholders will vote on re-electing PricewaterhouseCoopers SA as auditors and Blum & Partner AG as independent proxy, and on board compensation proposals (USD 572,000 fixed, USD 2,150,000 equity-based).
A shareholder information session will be held on May 11, 2026 in Reykjavík, Iceland, and virtually.
The company highlighted 2025 clinical progress, including completed enrollment in OCS-01 Phase 3 trials (DIAMOND-1 and -2) with topline results expected in June 2026.
Oculis Holding AG renews ATM program with Leerink Partners for up to $100 million
On March 4, 2026, Oculis Holding AG entered into an Amended and Restated Sales Agreement with Leerink Partners, LLC for its at-the-market offering program.
Show detailsHide details
Under the ATM program, the company may offer and sell ordinary shares with an aggregate offering price of up to $100 million.
The sales will be made pursuant to a new Form F-3 registration statement filed with the SEC on March 4, 2026 (File No. 333-294011).
The company also furnished its 2025 IFRS consolidated financial statements and 2025 statutory financial statements as exhibits to the Form 6-K.
The financial statements were audited by PricewaterhouseCoopers SA, which issued an unqualified opinion.